Introduction
============

*Candida* species are ubiquitous fungi and the most common fungal pathogens affecting humans. *Candida*, in particular, affects high-risk patients who are either immunocompromised or critically ill. More than 100 species of *Candida* exist, but only a few are recognized as causing disease in humans. *Candida glabrata* and *Candida albicans* account for 70 to 80% of yeasts isolated from patients with invasive candidiasis. In recent decades, *C. glabrata* has become important because of its increasing world-wide incidence and because of its developing resistance to antifungals, including azoles, in the clinic.

Azole antifungal agents such as fluconazole and voriconazole are approved therapy for candidemia and invasive candidiasis caused by *C. glabrata* ([@b1-mmr-17-05-6585]). Mechanisms of azole resistance include i) increased drug export (efflux pumps), ii) lost drug targets (e.g., altered drug target binding site), iii) up-regulated homeostatic stress-response pathways to deal with azole-associated damage, and iv) changed biosynthetic pathways (particularly sterol synthesis) that circumvent or attenuate the effects of azole inhibition ([@b2-mmr-17-05-6585]).

The cellular toxicity of azole antifungals occurs primarily through their ability to affect the fungal cell membrane by inhibiting the biosynthesis of ergosterol, the principal sterol in the fungal cell membrane, leading to the depletion of ergosterol and an accumulation of possibly toxic sterol intermediates in the cytoplasmic membrane. Azole antifungal compounds (imidazoles and triazoles) inhibit cytochrome P-450 dependent sterol 14α-demethylase (Erg11p), an enzyme that catalyzes the oxidative removal of the 14α-methyl group of lanosterol in the ergosterol biosynthetic pathway ([@b2-mmr-17-05-6585]). Fungal cells exposed to azoles must either synthesize more endogenous ergosterol or import exogenous sterol if they are to survive antimycotic treatment.

Sterol uptake appears to confer resistance to antifungal drugs since mutant strains of *Candida* species lacking *AUS1* and *TIR3*, the sterol influx transporters ([@b3-mmr-17-05-6585]), or *UPC2*, the transcription factor that controls *AUS1* and *TIR3* expression ([@b3-mmr-17-05-6585]--[@b5-mmr-17-05-6585]), exhibit reduced uptake of cholesterol and are hypersensitive to azoles ([@b6-mmr-17-05-6585],[@b7-mmr-17-05-6585]), whereas enhanced *UPC2* or *AUS1* expression and cholesterol uptake have been implicated in the azole-resistant phenotype ([@b6-mmr-17-05-6585],[@b7-mmr-17-05-6585]). Furthermore, several studies have even suggested that pathogenic fungi can scavenge free sterols for the cell membrane, including cholesterol, resulting in resistance to polyene and azole antifungals ([@b8-mmr-17-05-6585]). Increased uptake of exogenous cholesterol may be associated with drug resistance in clinical isolates of bile-dependent *C. glabrata* cells as well as in sterol auxotrophic *C. glabrata* strains ([@b9-mmr-17-05-6585]). These observations indicate that the ability to scavenge exogenous sterols, when ergosterol biosynthesis is defective or is blocked by antimycotic agents, may play an important role in increased azole resistance in pathogenic fungal species.

Besides sterol uptake, alteration in sterol biosynthesis seems to also affect fungal susceptibility to antifungals. *ERG11* is one of the critical genes in the ergosterol biosynthetic pathway, and its encoding protein product Erg11p (or CYP51p depending on nomenclature) is the major target enzyme of azole antifungals. Mutations in *ERG11* are the most common mechanism of azole resistance in *C. albicans* ([@b10-mmr-17-05-6585]). Over-expression of *ERG11* has been attributed to decreases in azole activity in *C. albicans*. Alterations in other enzymes of the ergosterol biosynthetic pathway, particularly *ERG3* (C-5 sterol desaturase), *ERG5* (C-22 sterol desaturase), *ERG6* (C-24 sterol methyl-transferase), and *ERG25* (C-4 sterol methyloxidase), which are up-regulated with inhibition of Erg11p, have also been documented to reduce azole susceptibility of *C. albicans*. In *C. glabrata*, depletion of the ergosterol content in a *CgERG1* mutant increases the levels of susceptibility to azoles, while complementation of the *CgERG1* mutation restores drug sensitivity to wild-type levels ([@b8-mmr-17-05-6585]). In both *C. albicans* and *C. glabrata*, regulation of sterol synthesis is vital to azole susceptibility.

In this study, we assessed the role of two protective mechanisms in conferring antifungal susceptibility in *C. glabrata*. We showed that expression of the genes involved in both sterol uptake and sterol synthesis is up-regulated in *C. glabrata* when ergosterol is depleted by azole treatment and when ergosterol biosynthesis is defective. We further corroborated that pathogenic fungi can accumulate exogenous sterols from the environment as a protective strategy to survive under azole and hypoxic stress. These findings suggest that sterol uptake and sterol synthesis may act coordinately and collaboratively to sustain growth and to mediate antifungal tolerance in *C. glabrata* through dynamic gene expression in response to azole pressure and environmental changes.

Materials and methods
=====================

### Cell culture and drug treatment

All *C. glabrata* strains ([Table I](#tI-mmr-17-05-6585){ref-type="table"}) used in the present study were cultured on YPD agar containing 1% Bacto yeast extract (Difco Laboratories, Detroit, MI, USA), 2% Bacto peptone (Difco Laboratories), and 2% glucose (Sigma-Aldrich, St. Louis, MO, USA). NCCLS84, Cg1660, CgTn201S, and CgTn201Su/aus1 were also grown on minimal (MIN) agar containing 0.67% Yeast Nitrogen Base without amino acids (Difco Laboratories) plus 2% glucose. The *ura3* mutants Cg84u, Cg1660u, and CgTn201Su were grown in MIN medium supplemented with 20 µg/ml of uracil (Sigma-Aldrich) or were selected on a MIN plus uracil agar plate containing 0.1% 5-fluoroorotic acid (FOA) (Lancaster, Pelham, NH, USA). YEPG agar was used for drug sensitivity assay, which contained 1% Bacto yeast extract (Difco Laboratories), 2% Bacto peptone (Difco Laboratories), 3% glycerol (Invitrogen/Life Technologies, Carlsbad, CA, USA), 1% ethanol (Warner-Graham, Inc., Cockeysville, MD), and 2% agar (Difco Laboratories).

Fluconazole (Euroasian Chemicals Private Ltd., Mumbai, India) was added to cultures of each strain at a final concentration of 200 µg/ml, followed by continued incubation with shaking for 2 h. Cell cultures without fluconazole treatment served as controls. After incubation, the cells were harvested, and the cell pellets were stored at −80°C until the subsequent isolation of RNA.

The BBL GasPak Plus gas generator envelope (Becton Dickinson Microbiology Systems, Sparks, MD, USA) or the BBL GasPak Pouch Anaerobic Systems (Becton Dickinson Microbiology Systems, Cockeysville, MD, USA) was used for cultures grown under conditions of low oxygen tension (hypoxia). To mimic the host environment of animals and humans, *C. glabrata* cells were also grown in the presence of 5% CO~2~ under low oxygen conditions using an InvivO2 400 workstation at 37°C with shaking at 200 rpm (Ruskinn Technology Ltd., Bridgend, UK). For analysis of sterol uptake and exogenous sterol utilization, 2 mg of ergosterol or cholesterol was dissolved in a mixture of 50% ethanol and 50% Tween-80 (Sigma-Aldrich) to give a 2 mg/ml stock solution, which was used to supplement the media with a final sterol concentration of 20 µg/ml. For comparison, the same final concentration of ethanol-Tween-80 without sterol was used.

### Drug sensitivity assay

The susceptibility of the *C. glabrata* strains Cg1660, CgTn201S, and CgTn201Su/aus1 to fluconazole and voriconazole was determined on MIN and YEPG agar media using an E-test (AB Biodisk, Solna, Sweden) according to the manufacturer\'s instructions. In brief, logarithmic-phase cells were harvested and adjusted to the desired concentrations by counting the number of cells with a hemocytometer. From each cell suspension, 200 µl (1×10^6^ cells/ml) was plated in duplicate on MIN and YEPG agar. All plates were incubated under conditions of low oxygen tension at 37°C for 3 days. Growth inhibition zones (minimum inhibitory concentration, MIC) to fluconazole and voriconazole were measured.

### RT-qPCR analysis

Total RNA was extracted from *C. glabrata* (Cg84u) logarithmic-phase cultures grown in YPD broth using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer\'s instructions. RNA was converted to cDNA using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems; Thermo Fisher Scientific, Inc.) as previously described ([@b11-mmr-17-05-6585]). Primers and probes were designed in our laboratory using the primer analysis software Primer Express 3.0 (Applied Biosystems; Thermo Fisher Scientific, Inc.). TaqMan probes were synthesized by Applied Biosystems (Thermo Fisher Scientific, Inc.) and primers were synthesized by Invitrogen (Thermo Fisher Scientific, Inc.). The sequences of TaqMan probes and forward and reverse primers, as well as the gene numbers for all genes assessed in this study, are listed in [Table II](#tII-mmr-17-05-6585){ref-type="table"}. To study gene expression, the amplification was detected in real time using both SYBR Green chemistry (SYBR-Green PCR Master Mix; Applied Biosystems; Thermo Fisher Scientific, Inc.) and TaqMan chemistry (TaqMan Universal PCR Master Mix; Applied Biosystems; Thermo Fisher Scientific, Inc.) as described previously ([@b11-mmr-17-05-6585]).

### Microarray hybridization and data analysis

DNA microarray analysis was used to identify genes with altered expression in the *C. glabrata erg1* mutant strain CgTn201S and the wild-type strain Cg1660. Total RNA was isolated from the log phase culture of *C. glabrata* grown in YPD by using TRIzol (Invitrogen; Thermo Fisher Scientific, Inc.) and the RNeasy MiniElute Cleanup kit (Qiagen, Valencia, CA, USA). RNA was assessed for quality using the Agilent 2100 Bioanalyzer with the RNA 6000 Nano Reagent Kit. Pin-spotted 70-mer oligonucleotide in-house arrays fabricated at the National Institute of Allergy and Infectious Diseases (NIAID) were used for analysis of the pair strains. In brief, a total of 5,908 70-mer oligonucleotides were purchased from Institut Pasteur (Paris, France) and were used for microarray printing at the NIAID Microarray Research Facility. Expression of each open reading frame (ORF) was measured by hybridization to a specific 70-mer oligonucleotide. Thirty micrograms of total RNA from the *erg1* mutant strain CgTn201S and the wild-type strain Cg1660 was reverse-transcribed to cDNA to incorporate the fluorescent Cy3-dUTP and Cy5-dUTP (GE Healthcare, Piscataway, NJ, USA), respectively. The labeled cDNA of the paired mutant/wild-type strain was combined and used for microarray hybridization. Six microarrays were performed for analysis of the *erg1* mutant/wild-type pair, including two with reciprocal labeling. The microarrays were prehybridized at 42°C in prehybridization buffer \[5 × SSC (1 × SSC is 0.15 M NaCl plus 0.015 M sodium citrate), 1% bovine serum albumin (BSA), 0.1% SDS\] for 30 to 60 min and then hybridized to the labeled cDNA in 50 µl of hybridization buffer \[25% formamide, 5 × SSC, 0.2% SDS, 20 µg/ml poly (dA)~40-60~, 200 µg/ml Cot-1 DNA (Invitrogen; Thermo Fisher Scientific, Inc.), 80 µg/ml yeast tRNA\] overnight at 42°C. The microarrays were washed three times in wash buffer A (1 × SSC, 0.05% SDS) and wash buffer B (0.1 × SSC). The in-house arrays were scanned with a GenePix 4000B scanner (Molecular Devices, Sunnyvale, CA, USA). All microarray data archive and statistical calculations were performed on the 'processed signal' data by using the Web-based mAdb analysis system provided by the Bioinformatics and Molecular Analysis group (BIMAS) at the Center for Information Technology (CIT), National Institutes of Health. The data were filtered with the parameters that included genes present in four or more arrays and each array with 80% or more genes present. The data set of the paired strains was then analyzed by Student\'s t-test. The genes with P-values less than 0.001 and with at least 1.5-fold altered gene expression were then selected. The final data set included all genes with altered expression in the pair.

### Cloning of CgAUS1

The full nucleotide sequence of the *C. glabrata AUS1* homolog (*CgAUS1*) was obtained from the Candida Genome Database ([www.candidagenome.org](www.candidagenome.org)). A 1,087 bp partial ORF of the *CgAUS1* gene was obtained by PCR with PfuUltra High-Fidelity DNA polymerase (Stratagene, La Jolla, California, USA), primer set CgAUS1S (5′-TTGAAGTTGCCTCTTGACTC-3′) and CgAUS1AS (5′-AAGGCAACAAACACAGCGGCAG-3′), and the total genomic DNA of Cg1660 was used as the template. The PCR parameters were 2 min at 95°C, followed by 30 cycles of 95°C for 30 sec, 53°C or 55°C for 30 sec, and 72°C for 1 min 30 sec, and then extended at 72°C for 10 min. The 1,087 bp PCR product, which was used as a probe for Southern blotting, was then cloned into pCR-Blunt II-TOPO (Invitrogen; Thermo Fisher Scientific, Inc.) to produce plasmid pCgAUS1.

### Construction of the Candida glabrata Cgerg1 and Cgaus1∆ double mutant

The *Cgerg1* mutant was generated in our laboratory as described previously ([@b8-mmr-17-05-6585]). Gene deletion of *Cgaus1* was performed as described by Vermitsky *et al* ([@b12-mmr-17-05-6585]). Briefly, the primer pair CgAUS1D1S (TTGAAATTCTCGGAAAGAAACATCAAATCAAAAAATTTTAACCTTCTAAAACTTGTTCTTTTTTTGGGAAATATAAGATGTCGAAAGCTACATATAAGGA) and CgAUS1D2AS (AGTAGATTAAAGAAAAGTGTTAAATTTAAGAATAAAATGGAATTGTTATTTCATTAAAAGCTTGTAGGAGTCACTCTTATTAGTTTTGCTGGCCGCATCT) was used to generate the *CgAUS1* deletion cassette using YEP24 as the template to amplify *Saccharomyces cerevisiae URA3*, which served as the selection marker. An additional round of PCR using the primer pair CgAUS1D3S (CCCCAACTATCAATTTTCTTTAAATCAAGGAAAATCTATTACATTCGCTATTAATCTCTACTATCTTTATCTTAGTTTTTTGAAATTCTCGGAAAGAAAC) and CgAUS1D4AS (ATTATATTTTAAATTTTGTTGTATAGCTTTTTTGCTGTAAAGGTGAAAAAACCGGGAATTTTGAGCATTAGTATTAGTAGATTAAAGAAAAGTGTTAAAT) extended the 5′ and 3′ ends with about a 160 bp homologous region on each end of the *CgAUS1* deletion cassettes to increase the efficiency of homologous recombination. *S. cerevisiae URA3* was transformed into CgTn201Su (*Cgura3 Cgerg1*::Tn5\<Cm ura3\>) to construct the *Cgerg1/aus1* double mutant CgTn201Su/aus1 via a successful double crossover homologous recombination, which resulted in replacement of the *CgAUS1* ORF with *S. cerevisiae URA3* ([Fig. 1A](#f1-mmr-17-05-6585){ref-type="fig"}). The *CgERG1* locus in the clinical isolate Cg1660 and its transposon mutant CgTn201S (*Cgerg1*) are shown in [Fig. 1B](#f1-mmr-17-05-6585){ref-type="fig"}. Transformants were selected on MIN medium, and the deletion of *CgAUS1* was confirmed by Southern blot analysis of the EcoRI-digested genomic DNA ([Fig. 1C](#f1-mmr-17-05-6585){ref-type="fig"}). The purified 1.2-kb *ScURA3* probe detected a single signal in the *Cgerg1* mutant CgTn201S; two signals were detected in the two putative *Cgerg1/aus1* mutants CgTn201Su/aus1-1 and CgTn201Su/aus1-2, while there was no signal in the parental strain Cg1660 ([Fig. 1C](#f1-mmr-17-05-6585){ref-type="fig"}, right panel). The 1087-bp *CgAUS1* probe detected a single 6.3-kb signal in Cg1660 and CgTn201S, but not in the two putative *Cgerg1/aus1* mutants CgTn201Su/aus1-1 and CgTn201Su/aus1-2 ([Fig. 1C](#f1-mmr-17-05-6585){ref-type="fig"}, left panel).

### Southern blot analysis

*Candida glabrata* genomic DNA was isolated from cultures grown in YPD overnight by using the MasterPure Yeast Purification Kit (Epicentre, Madison, WI, USA). Purified DNA fragments were recovered using the Strataprep Gel DNA Extraction kit (Stratagene; Agilent Technologies, Inc., Santa Clara, CA, USA). Hybond-N nylon membranes (Amersham, Arlington Heights, IL, USA) were used for Southern hybridization analyses. DNA probes were labeled with \[α-^32^P\] dCTP or \[α-^32^P\] dATP (MP Biomedical, Solon, OH, USA) by using the Prime-It II kit (Stratagene; Agilent Technologies, Inc.). DNA cloning and hybridization analyses were done according to the standard protocol.

### Other techniques and reagents

DNA sequencing was done using the DNA sequencing kit with a dRhodamine dye terminator (Applied Biosystems; Thermo Fisher Scientific, Inc.) and an ABI automatic DNA sequencing system (Perkin-Elmer, Foster City, CA, USA). For sequencing of PCR products, PfuUltra DNA polymerase (Stratagene; Agilent Technologies, Inc.) was used for PCR amplification to minimize the rate of PCR-introduced mutations. The PCR products were cleaned with the Strataprep PCR Purification kit (Stratagene; Agilent Technologies, Inc.) and were used as templates for DNA sequencing.

### Bioinformatic and statistical analysis

The Gene Ontology (GO) enrichment analysis and the network visualization of the biological functions related to the differentially expressed genes were performed using Cytoscape software with associated plug-ins ([@b13-mmr-17-05-6585]). To create a functional network by selecting the ClueGO: Function, GO: Biological process, all the network evidence and only the terms with various levels of significance (P\<0.1-\<0.0005) were taken into consideration using the plug-in ClueGO ([@b14-mmr-17-05-6585]), which was followed by enrichment of the functional network with the plug-in CluePedia ([@b15-mmr-17-05-6585]).

Results of RT-qPCR for each gene are presented as the fold-change over the expression in the sample not treated with fluconazole, which was set as 1. The difference in triplicate C~q~ values (∆C~q~) was used to calculate the difference between untreated and azole-treated samples. Student\'s t-test was used to analyze the statistical significance of differences between untreated and fluconazole-treated *C. glabrata* cells, and P-values were adjusted using Holm\'s adjustment for multiple testing. Values of P\<0.05 were taken to indicate significance.

Results
=======

### Azole stress up-regulates the genes involved in sterol uptake and biosynthesis

Ergosterol biosynthetic genes encode the enzymes in the sterol synthetic pathway leading to ergosterol biosynthesis in yeast. It is of interest to understand whether the inhibition of ergosterol biosynthesis by azoles alters endogenous sterol synthesis in *C. glabrata* through changes in the expression of ergosterol biosynthetic genes. We found that mRNA levels of *CgERG2, CgERG3, CgERG4, CgERG10*, and *CgERG11* were strikingly increased in *C. glabrata* following fluconazole treatment. As seen in [Table III](#tIII-mmr-17-05-6585){ref-type="table"}, the extent of inducible up-regulation of *ERG* gene expression by fluconazole in these cells ranged from more than 5-fold in *CgERG3* to 19-fold in *CgERG10* compared with the untreated controls. Interestingly, we also showed a 3.7-fold increase in mRNA expression of *CgPDR16* in fluconazole-treated *C. glabrata* cells ([Table III](#tIII-mmr-17-05-6585){ref-type="table"}); PDR16p is an ATP-binding cassette (ABC) transporter involved in the sterol biosynthetic process and phospholipid transport in *S. cerevisiae* ([@b16-mmr-17-05-6585]).

*AUS1* and *UPC2* (or its paralog *ECM22*) have been demonstrated to be responsible for sterol uptake in *S. cerevisiae* ([@b17-mmr-17-05-6585]). We next addressed whether inhibition of sterol synthesis by azoles alters the expression of these genes in *C. glabrata*. Sequencing data have shown that *C. glabrata* is more closely related to *Saccharomyces cerevisiae* than to *C. albicans*, and some genes are functionally exchangeable between *C. glabrata* and *S. cerevisiae*. Therefore, to identify *AUS1* and *ECM22/UPC2* orthologs in *C. glabrata*, we selected the *S. cerevisiae AUS1, ECM22*, and *UPC2* genes as queries to perform homology searches. A BLAST search against the *C. glabrata* open reading frame (ORF) nucleotide and amino acid sequences ([www.candidagenome.org](www.candidagenome.org)) predicted CAGL0F01419g (*CgAUS1*) to be the ortholog of *AUS1*. We also performed a BLAST search against *C. glabrata* ORF nucleotide sequence alone, which predicted CAGL0C01199g and CAGL0F07865g to be possible orthologs of *ECM22* or *UPC2*. The amino acid sequences encoded by these two genes are particularly highly homologous to Upc2p or Ecm22p. We refer to CAGL0C01199g and CAGL0F07865g as *UPC2A* (*ECM22*) and *UPC2B* (*ECM22*), respectively. This is in concordance with the work of Nagi *et al* ([@b4-mmr-17-05-6585]) and Whaley *et al* ([@b18-mmr-17-05-6585]). Our results demonstrate a transcriptional up-regulation of over two-fold and over four-fold in *CgAUS1* and *CgUPC2A* expression, respectively, in our model following fluconazole challenge ([Table III](#tIII-mmr-17-05-6585){ref-type="table"}). These data clearly show that inhibition of ergosterol synthesis by azoles induce the expression of sterol transporter genes and likely lead to enhanced sterol uptake in *C. glabrata*.

Besides its role in anaerobic sterol uptake, *UPC2* has been shown to be an activator of ergosterol biosynthetic genes in yeast ([@b4-mmr-17-05-6585],[@b18-mmr-17-05-6585]). As the up-regulation of *CgUPC2* expression was induced by fluconazole in *C. glabrata*, this result prompted us to address whether azoles alter the expression of other genes encoding transactivators responsible for sterol synthesis or uptake in fungi. It has been demonstrated that *SUT1* is a transcription factor involved in sterol uptake and synthesis in aerobically growing *S. cerevisiae* cells ([@b19-mmr-17-05-6585]). Therefore, to identify *SUT1* ortholog in *C. glabrata*, we selected the *S. cerevisiae SUT1* gene as queries to perform homology searches. A BLAST search against the *C. glabrata* ORF nucleotide sequence ([www.candidagenome.org](www.candidagenome.org)) predicted CAGL0I04246g and CAGL0L09383g to be possible orthologs of *SUT1*. The amino acid sequences encoded by these two genes are particularly highly homologous to Sut1p. We refer to CAGL0I04246g and CAGL0L09383g as *CgSUT1* and *CgSUT2*, respectively. In the current model, we show that the expression of *CgSUT1*, but not *CgSUT2*, was significantly increased by fluconazole in *C. glabrata* ([Table III](#tIII-mmr-17-05-6585){ref-type="table"}).

### Up-regulated expression of the genes involved in sterol uptake and biosynthesis in Candida glabrata erg1 mutant

To further assess whether ergosterol depletion affects the genes involved in sterol uptake and sterol synthesis in *C. glabrata*, we used DNA microarray to analyze gene expression in a *C. glabrata erg1* mutant with defective ergosterol biosynthesis. Transcriptional profiling of the microarrays revealed 35 genes up-regulated and 4 genes down-regulated in the *C. glabrata erg1* mutant CgTn201S compared to the parental wild-type strain Cg1660. Particularly, *C. glabrata erg1* mutant had 2.5-fold up-regulation of *CgAUS1* mRNA, 5.6-fold up-regulation of *CgTIR3* mRNA, and 3.5-fold up-regulation of *CgUPC2B* mRNA over the wild-type cells ([Fig. 2](#f2-mmr-17-05-6585){ref-type="fig"}). To a lesser extent, we also found that the up-regulation of *CgERG2, CgERG3, CgERG5, CgERG6, CgERG7, CgERG10, CgERG11*, and *CgERG29* in the *C. glabrata erg1* mutant cells ranged from 1.5-to 2.8-fold mRNA expression among these genes ([Table IV](#tIV-mmr-17-05-6585){ref-type="table"}), which is similar to our data from the *C. glabrata* cells in which ergosterol synthesis was inhibited by fluconazole ([Table III](#tIII-mmr-17-05-6585){ref-type="table"}). Additionally, we show a 3-fold increase in mRNA expression of *HES1*/*KES1*, which is involved in ergosterol biosynthesis, oxysterol binding, and sterol transport ([Table IV](#tIV-mmr-17-05-6585){ref-type="table"}). These data highlight the notion that blocking ergosterol synthetic pathway leading to ergosterol depletion causes increased sterol uptake activity and sterol biosynthesis in *C. glabrata*.

Besides the genes for sterol uptake and synthesis, 23 other genes demonstrated dominant and reproducible expression in *C. glabrata erg1* mutant with the average level of the six microarrays ranging from 1.5-fold to 6.3-fold greater than the wild-type strain ([Table IV](#tIV-mmr-17-05-6585){ref-type="table"}). These differentially expressed genes were associated with multiple different cellular metabolisms and biological processes, such as iron, amino acid, and carbohydrate metabolisms, alcohol metabolism, reactive oxygen species (ROS) metabolism, heme biosynthesis, biotin biosynthesis, mitochondrion organization, mitochondrial electron transport, oxidation-reduction process, cation homeostasis, cell wall integrity, and in-cell polarity, endoplasmic reticulum, mitochondrion, nucleus localization, and so forth ([Table IV](#tIV-mmr-17-05-6585){ref-type="table"}). Furthermore, mRNA expression of 4 genes was down-regulated 1.5- to 2.2-fold lower than the parental wild-type cells ([Table IV](#tIV-mmr-17-05-6585){ref-type="table"}). These down-regulated genes were enriched in several cellular and metabolic processes, including lipid metabolism, sphingolipid and fatty acid transport, respiratory growth, ATP/ADP exchange, and cellular response to oxidative stress ([Table IV](#tIV-mmr-17-05-6585){ref-type="table"}).

### Potential coordination between sterol biosynthesis and sterol uptake in Candida glabrata erg1 mutant

To further explore the functional themes of the above 35 differentially expressed genes in *C. glabrata erg1* mutant, we used Cytoscape, a bioinformatics software for visualizing functional and molecular interaction networks. The functional interaction networks in [Fig. 3](#f3-mmr-17-05-6585){ref-type="fig"} support our interpretation that the ergosterol biosynthetic process is the major biological function affected in *C. glabrata* mutant strain lacking *ERG1*. To compensate for the defective sterol biosynthetic pathway in the cell, and overcome the imbalance in cellular levels of sterol, cells increase the sterol uptake machinery and ergosterol biosynthesis processes in order to survive under azole and environmental stress. As shown in [Fig. 3](#f3-mmr-17-05-6585){ref-type="fig"}, nine genes (*ERG2, ERG3, ERG5, ERG6, ERG7, ERG10, ERG11, ERG29*, and *CYB5*) comprise the largest network cluster and contribute towards the enrichment of the 'sterol biosynthetic process.' While three genes (*AUS1, DAN1*, and *RSB1*) in the other smaller functional network cluster are enriched with 'lipid localization' in combination with GO-term 'sterol transport' ([Fig. 3](#f3-mmr-17-05-6585){ref-type="fig"}). *KES1* and *HES1* are the genes bridging the two major clusters by establishing a potential coordination between the 'sterol biosynthetic process' and 'lipid localization/sterol transport' ([Fig. 3](#f3-mmr-17-05-6585){ref-type="fig"}). The enriched processes identified with the Cytoscape software and GO database using the differentially expressed genes in *C. glabrata erg1* mutant are shown in [Table V](#tV-mmr-17-05-6585){ref-type="table"}.

### Candida glabrata aus1 deletant is defective in sterol uptake and has greater susceptibility to azoles under hypoxic conditions

Lastly, we validated whether *C. glabrata* cells accumulate sterols from the environment through the Aus1p transporter and whether sterol uptake confers resistance to azoles in *C. glabrata*. To distinguish the uptake of exogenous sterol from that of endogenous ergosterol biosynthesis, we generated a *C. glabrata erg1/aus1Δ* double mutant strain and used the *C. glabrata erg1* mutant strain CgTn201S and the wild-type strain Cg1660 as the controls. As seen in [Fig. 4A and B](#f4-mmr-17-05-6585){ref-type="fig"} and [Tables VI](#tVI-mmr-17-05-6585){ref-type="table"} and [VII](#tVII-mmr-17-05-6585){ref-type="table"}, in the presence of exogenous cholesterol or ergosterol, *C. glabrata erg1* mutant cells showed much lower susceptibility to fluconazole and voriconazole compared to those cells in the absence of exogenous sterols, suggesting that *C. glabrata erg1* mutant cells are capable of accumulating sterols from the medium through the wild-type sterol transporter CgAus1p; but not through ergosterol synthesis because the cells were defective in ergosterol synthetic pathway. In contrast, in the presence of exogenous cholesterol or ergosterol, the *C. glabrata erg1/aus1Δ* double mutant shows much higher susceptibility to fluconazole and voriconazole than the *C. glabrata erg1* mutant, indicating that *C. glabrata erg1Δaus1Δ* double mutant cells are not able to uptake and synthesize sterols due to defective conditions in both the CgAus1p transporter and ergosterol biosynthesis in the cells. We also tested whether the loss of CgAus1p in *C. glabrata* sensitizes the pathogen to polyene amphotericin B and the echinocandins anidulafungin and caspofungin, and our E-test results reveal that *C. glabrata* cells lacking CgAus1p do not show altered susceptibility to non-azole antifungals in the presence or absence of exogenous sterols (data not shown). These observations confirm the findings of Zavrel *et al* ([@b20-mmr-17-05-6585]) that CgAus1p is responsible for taking up exogenous cholesterol or ergosterol in *C. glabrata* under hypoxic stress when sterol synthesis is either absent or insufficient, and further suggest that sterol uptake plays an important role in the development of azole resistance in yeast under ergosterol starvation conditions, such as under azole drug pressure or when defective in sterol biosynthesis.

Discussion
==========

Yeast develops strategies to grow and survive in different unfavorable environments. In the present study, we observed that *C. glabrata* acquires two protective mechanisms to allow the pathogen to grow and survive under azole and hypoxic stress: Through increasing endogenous sterol synthesis or through importing exogenous sterols. Our data revealed that the expression of both ergosterol biosynthesis and sterol metabolism regulator genes, as well as sterol influx transporter genes, are significantly increased in *C. glabrata* under fluconazole stress. Likewise, the sterol influx transporter genes (*CgAUS1* and *CgTIR3*) and the ergosterol biosynthetic genes (*CgERG2, CgERG3, CgERG5, CgERG6, CgERG7, CgERG10, CgERG11*, and *CgERG29*) are markedly up-regulated in yeast when ergosterol biosynthesis is suppressed either under hypoxia or due to defective sterol synthesis. We also confirmed that *CgAUS1* in the cell is responsible for importing exogenous cholesterol and ergosterol, thus allowing *C. glabrata* to survive under low oxygen tension conditions or under azole pressure. The presence of both *in vivo* suggests an underlying mechanism for azole resistance in clinical practice.

Nakayama and colleagues show that *CgAUS1* protects *C. glabrata* cells against azoles in the presence of serum ([@b21-mmr-17-05-6585]). The composition of serum is complicated, and it includes many different molecules, minerals, and nutrients other than cholesterol. It is possible that, besides importing cholesterol via the sterol transporter *CgAUS1, C. glabrata* cells may also take up other molecules and nutrients from serum that are necessary to their survival amidst azole treatment. In our experiments, as in those of Zavrel *et al* ([@b20-mmr-17-05-6585]), we did not use serum but solubilized cholesterol and ergosterol using the detergent Tween 80. This allowed for the incorporation of exogenous sterol into the fungal cell. Our results, together with the data discussed above, reinforce the understanding of how both enhanced endogenous sterol synthesis and increased exogenous sterol uptake by yeast are integral to conferring resistance to azole therapy in fungal infections. Resistance to azole treatment not only limits the usefulness of this class of drugs, it also drives the survival of intrinsically low-susceptibility *C. glabrata* cells that become increasingly resistant following prolonged treatment with azole therapeutic agents.

Combining our data in this study, we propose a hypothetical model in which sterol uptake and sterol biosynthesis act coordinately and collaboratively to mediate azole antifungal resistance in *C. glabrata* under azole and hypoxic stress as shown in [Fig. 5](#f5-mmr-17-05-6585){ref-type="fig"}. In this model, azole and hypoxic stresses deplete ergosterol directly or indirectly by inhibiting ergosterol biosynthesis. Hypoxia and azoles cause mitochondrial dysfunction by depriving the mitochondria of oxygen and inducing the accumulation of toxic sterol-intermediates, ultimately leading to the reduction of ergosterol biosynthesis. In response, ergosterol depletion triggers up-regulation of the genes involved in sterol transport and ergosterol biosynthesis, leading to increases in sterol levels. Because both sterol uptake and sterol biosynthesis increase sterol levels through distinct mechanisms, they both may function together to maintain sterol levels and sustain cell growth. Such a cooperative mechanism may serve to integrate the roles of sterol transport and sterol biosynthesis culminating in cell survival, which may underlie the mechanism of azole antifungal resistance in *C. glabrata*.

Collectively, this study shows the up-regulation of the genes involved in ergosterol biosynthesis and sterol transport in *C. glabrata* cells in which sterol synthesis is defective or is abrogated by fluconazole treatment. We also corroborate that the sterol influx transporter CgAus1p imports exogenous cholesterol or ergosterol, which contributes to the development of clinical resistance to azole antifungals in *C. glabrata*. These findings demonstrate that sterol uptake and sterol biosynthesis may act coordinately and collaboratively to sustain growth and to mediate antifungal resistance in *C. glabrata* through dynamic gene expression in response to azole stress and environmental challenges.
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![Southern hybridization analysis confirms the deletion and targeted gene replacement of CgAUS1 in Candida glabrata. (A) Deletion strategy of CgAUS1 in the strain CgTn201Su (Cgerg1/ura3). The CgAUS1 ORF was replaced with ScURA3 in the mutant CgTn201Su/aus1 (Cgerg1 Cgaus1Δ). (B) The CgERG1 locus in the clinical isolate Cg1660 and its transposon mutant CgTn201S (Cgerg1). (C) Southern blot analysis. The genomic DNAs of Cg1660, CgTn201S, and the mutant CgTn201Su/aus1 were digested with EcoRI, electrophoresed, and blotted onto a nylon membrane. The membrane was hybridized with the 1087-bp CgAUS1 probe (left panel) or 1.2-kb ScURA3 probe (right panel). Lanes (from the left): 1. Cg1660, clinical isolate; 2. CgTn201S, Cgerg1 mutant; 3. and 4. CgTn201Su/aus1, Cgerg1 Cgaus1Δ double mutant. The detected signals for CgAUS1 (left panel) and ScURA3 (right panel) are indicated by arrows.](MMR-17-05-6585-g00){#f1-mmr-17-05-6585}

![Expression of CgAUS1, CgTIR3, and CgUPC2B is up-regulated in Candida glabrata erg1 mutant. DNA microarray was used to analyze gene expression in the C. glabrata erg1 mutant CgTn201S and its parental wild-type strain Cg1660 as described in Materials and methods. Six microarrays were performed for analysis of the Cgerg1 mutant/wild-type pair, including two with reciprocal labeling. The average mRNA expression levels were based on mean of six replicates. Transcriptional profiling of the microarrays revealed the up-regulation (fold-change) of CgAUS1, CgTIR3, and CgUPC2B in CgTn201S (Cgerg1) as compared with Cg1660 (wild-type), which was set as 1. \*P\<0.01 between the C. glabrata erg1 mutant CgTn201S and its parental wild-type strain Cg1660 using Student\'s t-test.](MMR-17-05-6585-g01){#f2-mmr-17-05-6585}

![Two major functional networks obtained from the 35 differentially expressed genes in Candida glabrata erg1 mutant using Cytoscape software. Each node (filled circle) represents a biological process and the size and color code indicate, respectively, the number of genes mapped and the significance of the terms (lower right inset). The direction of the network is shown by arrow-head of edges; the edge-thickness is based on kappa-score level calculated automatically by ClueGO. The molecular interaction network between the 'sterol biosynthetic process' and 'lipid localization' in combination with 'sterol transport' is shown in the upper right inset.](MMR-17-05-6585-g02){#f3-mmr-17-05-6585}

![CgAUS1 deletion in Candida glabrata abolishes the effect of sterol supplement on azole susceptibility under hypoxic conditions. Cg1660 (wild-type), CgTn201S (Cgerg1), or CgTn201Su/aus1 (Cgerg1/aus1Δ) were grown on (A) MIN agar medium or (B) YEPG agar medium. Plates were incubated under conditions of low oxygen tension at 37°C for 3 days. The fluconazole and voriconazole susceptibilities of Cg1660, CgTn201S, and CgTn201Su/aus1 were analyzed by E-test. The intercept of the zone of growth inhibition with the paper strip indicates the minimum inhibitory concentration (MIC). The addition of cholesterol or ergosterol is indicated by the position within each of the four groups as follows: upper left corner, MIN or YEPG; upper right corner, MIN or YEPG with ethanol-Tween 80 solvent alone; lower left corner, MIN or YEPG with cholesterol; and lower right corner, MIN or YEPG with ergosterol. The numerical data are shown in [Tables VI](#tVI-mmr-17-05-6585){ref-type="table"} and [VII](#tVII-mmr-17-05-6585){ref-type="table"} for MIN agar cultures and YEPG agar cultures, respectively.](MMR-17-05-6585-g03){#f4-mmr-17-05-6585}

![A schematic diagram illustrating a hypothetical model for sterol uptake and sterol biosynthesis acting coordinately and collaboratively in mediating azole antifungal resistance in Candida glabrata under azole and hypoxic stress. See 'Discussion' for further elaboration.](MMR-17-05-6585-g04){#f5-mmr-17-05-6585}

###### 

*Candida glabrata* strains used in this study.

  Strain           Parental strain   Genotype or description                                                 Reference or source
  ---------------- ----------------- ----------------------------------------------------------------------- -------------------------------------------------------
  NCCLS84                            Wild-type (ATCC90030)^[a](#tfn1-mmr-17-05-6585){ref-type="table-fn"}^   ATCC^[a](#tfn1-mmr-17-05-6585){ref-type="table-fn"}^
  Cg84u            NCCLS84           *Cgura3*                                                                ([@b8-mmr-17-05-6585])
  Cg1660                             Clinical isolate                                                        FHCRC^[b](#tfn2-mmr-17-05-6585){ref-type="table-fn"}^
  Cg1660u          Cg1660            *Cgura3*                                                                ([@b8-mmr-17-05-6585])
  CgTn201S         Cg1660u           *Cgura3 Cgerg1*::Tn5\<Cm URA3\>                                         ([@b8-mmr-17-05-6585])
  CgTn201Su        CgTn201S          *Cgura3 Cgerg1*::Tn5\<Cm ura3\>                                         Present study
  CgTn201Su/aus1   CgTn201Su         *Cgura3 Cgerg1*::Tn5\<Cm ura3\>                                         Present study
                                     *Cgaus1*∆::URA3                                                         

American Type Culture Collection (ATCC), Manassas, VA, USA.

FHCRC, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

###### 

Primers and TaqMan probes for RT-qPCR analysis of gene expression used in this study.

  Gene       Primer and probe sequence (5′→3′)   Gene number^[a](#tfn3-mmr-17-05-6585){ref-type="table-fn"}^
  ---------- ----------------------------------- -------------------------------------------------------------
  *ACT1*                                         
    F        TTGGACTCTGGTGACGGTGTTA              CAGL0K12694g
    R        AAAATAGCGTGTGGCAAAGAGAA             
    P        CCACGTTGTTCCAATTTACGCCGG            
  *RDN5.8*                                       
    F        CTTGGTTCTCGCATCGATGA                CAGL0L13387r
    R        GGCGCAATGTGCGTTCA                   
    P        ACGCAGCGAAATGCGATACGTAATGTG         
  *ERG2*                                         
    F        TCCCAGGTATGACCCATCATC               CAGL0L10714g
    R        TGCGAAGGAGTTTTGATCCAT               
    P        ACAAAAGGGCTACGCAAAGCAATACGC         
  *ERG3*                                         
    F        TGCACTGGCCTCGTGTCTAC                CAGL0F01793g
    R        TAACCGTCGACTGGGTGGAA                
    P        TGGTTGGTCTGCACTCCATTCGCC            
  *ERG4*                                         
    F        CCCTCAATTAGGTGTCGTCATGT             CAGL0A00429g
    R        GGCACGATTAATTCTTCACCCTTA            
    P        CCACTGGCTGTACGCTAACGCTTGTG          
  *ERG10*                                        
    F        GCCAGAACCCCAATTGGTT                 CAGL0L12364g
    R        TGCAATGACACCTAGGTCAACAG             
    P        TTCCAAGGTGCGTTGGCCTCCA              
  *ERG11*                                        
    F        TGTCTTGATGGGTGGTCAACA               CAGL0E04334g
    R        CTGGTCTTTCAGCCAAATGCA               
    P        CTTCCGCTGCTACCTCCGCTTGG             
  *PDR16*                                        
    F        CCTGGAGACGTGAATTTGGAAT              CAGL0J07436g
    R        ACAGCAACCAAATCCGATGTAA              
    P        CTCGTCACCATTTTCTTCACCCAAATGG        
  *PDR16*                                        
    F        TTGGCCTGGAGACGTGAATT                CAGL0J07436g
    R        GTTTACCACTTTCATTCTCTACAGCAA         
    P        TTGGGTGAAGAAAATGGTGACGAGGTTACA      
  *AUS1*                                         
    F        CCAAGCCACTGCAGGTGAA                 CAGL0F01419g
    R        GGCGTGAAACAGGGACTTGA                
    P        CGGTGCCCCAACGTCGGGTATC              
  *SUT1*                                         
    F        GTTGATGGCATTACATGGCAAT              CAGL0I04246g
    R        AGTAAAGGAGTTGGATGATGAGTGAA          
    P        ACCAATTCCTATCGCCTCCAATGCCA          
  *SUT2*                                         
    F        AGGGCCTTCAAGGTATCGAAGT              CAGL0L09383g
    R        TCGGTTTTTGGATCACACCAA               
    P        TTGCCTCTCCAAAACAGAAACTACCCTCCC      
  *ECM22*                                        
    F        CAATTACAAGAGCATGCAAACATTG           CAGL0C01199g
    R        GGAGTTAGCCTGACCATGAGTATTATT         
    P        TGCATCAGAAACAGCATATCCAACGACTGT      
  *UPC2A*                                        
    F        AAAATAGTACAGGAGCAACGGAGACT          CAGL0C01199g
    R        TGGTTGCACCTGGAGATGAA                
    P        CTGTCGCCTTCTCTGAATCTGCTTACACCC      
  *UPC2B*                                        
    F        GGTCGCAAGTGCATTGTTGT                CAGL0F07865g
    R        TCAGTCGCATTTGATGTATCTTTAGG          
    P        CGTGGAATAATCACGATCCTCACATGCA        

Candida Genome Database ([www.candidagenome.org](www.candidagenome.org)). F, forward primer; R, reverse primer; P, TaqMan probe, labeled as 5′-FAM, 3′-TAMRA; RT-qPCR, reverse transcription-quantitative polyermase chain reaction.

###### 

Upregulated expression of sterol biosynthetic and sterol transporter genes in *Candida glabrata* under fluconazole stress.

  Gene      mRNA levels
  --------- --------------------------------------------------------
  *ERG2*    11.79^[a](#tfn6-mmr-17-05-6585){ref-type="table-fn"}^
  *ERG3*      5.04^[a](#tfn6-mmr-17-05-6585){ref-type="table-fn"}^
  *ERG4*    11.08^[a](#tfn6-mmr-17-05-6585){ref-type="table-fn"}^
  *ERG10*   19.07^[a](#tfn6-mmr-17-05-6585){ref-type="table-fn"}^
  *ERG11*     5.87^[a](#tfn6-mmr-17-05-6585){ref-type="table-fn"}^
  *PDR16*     3.73^[a](#tfn6-mmr-17-05-6585){ref-type="table-fn"}^
  *AUS1*      2.51^[b](#tfn5-mmr-17-05-6585){ref-type="table-fn"}^
  *SUT1*      2.60^[b](#tfn5-mmr-17-05-6585){ref-type="table-fn"}^
  *SUT2*      0.97
  *UPC2A*     4.71^[a](#tfn6-mmr-17-05-6585){ref-type="table-fn"}^
  *UPC2B*     1.60^[b](#tfn5-mmr-17-05-6585){ref-type="table-fn"}^

Values indicate the fold-change in RNA transcription for each gene in 200 µg/ml fluconazole-treated *C. glabrata* after normalization to RDN5.8 as the reference, as compared with the level in untreated cells, which was set as 1.

P\<0.05 or

P\<0.01 between fluconazole-treated and untreated *C. glabrata* cells for all values shown in this table.

###### 

*Candida glabrata* genes up- and down-regulated ≥1.5-fold in response to *CgERG1* disruption (*Cgerg1* mutation) in Cg1660 host.

  *C. glabrata* designation   *S. cerevisiae* homologue   Description                                                                                                   Fold expression^[a](#tfn7-mmr-17-05-6585){ref-type="table-fn"}^
  --------------------------- --------------------------- ------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------
  Upregulated genes                                                                                                                                                     
    CAGL0F01419g              AUS1                        ATP-binding cassette transporter involved in sterol uptake                                                    2.5006
    CAGL0C03872g              TIR3/YIL011w                Putative GPI-linked cell wall protein involved in sterol uptake                                               5.6547
    CAGL0F07865g              UPC2B                       Transcription factor transcriptionally regulates ergosterol biosynthetic genes and sterol transporter genes   3.4979
    CAGL0L10714g              ERG2                        C-8 sterol isomerase participates in ergosterol biosynthesis                                                  2.0136
    CAGL0F01793g              ERG3                        C-5 sterol desaturase participates in ergosterol biosynthesis                                                 2.7363
    CAGL0M07656g              ERG5                        C-22 sterol desaturase participates in ergosterol biosynthesis                                                2.3415
    CAGL0H04653g              ERG6                        C-24 sterol methyltransferase participates in ergosterol biosynthesis                                         2.1176
    CAGL0J10824g              ERG7                        Lanosterol synthase participates in ergosterol biosynthesis                                                   2.31
    CAGL0L12364g              ERG10/POT14                 Acetyl-CoA C-acetyltransferase participates in ergosterol biosynthesis                                        2.2113
    CAGL0E04334g              ERG11                       Lanosterol 14-a-demethylase involved in ergosterol biosynthesis                                               2.8477
    CAGL0K03927g              ERG29                       Roles in ergosterol biosynthesis, mitochondrion organization, etc                                             1.5044
    CAGL0J03916g              HES1/KES1                   Roles in ergosterol biosynthesis, oxysterol binding, sterol transport, etc                                    2.9779
    CAGL0J00297g              YHR045w                     Possible roles in iron, amino acid, and carbohydrate metabolisms                                              1.5889
    CAGL0A01089g              YPL272c                     Alcohol O-acetyltransferase with role in alcohol metabolic process                                            4.0299
    CAGL0I01408g              CYC1                        Cytochrome-*c* isoform 1 involved in mitochondrial electron transport                                         2.6164
    CAGL0L03828g              CYB5                        Cytochrome b5 involved in oxidation-reduction process                                                         1.5483
    CAGL0K10868g              CTA1                        Catalase A involved in cellular response to oxidative stress                                                  2.7464
    CAGL0K12100g              HEM13                       Coproporphyrinogen III oxidase involved in heme biosynthesis                                                  2.3296
    CAGL0G03905g              ISA1                        Regulation of ROS metabolic process and biotin biosynthetic process                                           1.5708
    CAGL0H04851g              PPZ1                        Protein phosphatase Z involved in cation homeostasis and cell wall integrity                                  1.633
    CAGL0L07480g              NRG1/NRG2                   Transcription factor activity, sequence-specific DNA binding activity                                         1.613
    CAGL0F01485g              TIR4                        Putative GPI-linked cell wall mannoprotein of the Srp1p/Tip1p family                                          5.4181
    CAGL0H09614g              TIR1                        Putative GPI-linked cell wall protein                                                                         6.3371
    CAGL0C00110g              FLO1                        Member of the FLO family of cell wall flocculation proteins                                                   1.9697
    CAGL0M04125g              YNL320w                     Roles in cell polarity, endoplasmic reticulum, mitochondrion, etc                                             1.5089
    CAGL0E00187g              YMR317w                     Putative adhesin-like protein; belongs to adhesin cluster IV                                                  4.3814
    CAGL0G04499g              SET4/YJL105w                Ortholog of *S. cerevisiae*: SET4 and YJL105w                                                                 1.9778
    CAGL0F08965g              MSC7/YHR039c                Roles in cytosol, endoplasmic reticulum, nucleus localization, etc                                            1.6906
    CAGL0C00209g              DAN1/YJR151c                Putative adhesin-like cell wall protein; predicted GPI-anchor                                                 4.6475
    CAGL0G10175g              DAN1/YJR151c                Adhesin-like protein; predicted GPI anchor                                                                    4.7887
    CAGL0K04279g              SCM4/YGR049w                Ortholog(s) have mitochondrial outer membrane localization                                                    1.5542
  Downregulated genes                                                                                                                                                   
    CAGL0H03971g              YCP4/PST2                   Roles in cellular response to oxidative stress, mitochondrion, etc                                            1.5484
    CAGL0M05995g              PET10                       Roles in lipid metabolism, respiratory growth, and ATP/ADP exchange                                           1.5975
    CAGL0G05566g              FMP45                       In mitochondria; role in ascospore formation, cellular response to drug, etc                                  1.5862
    CAGL0L10142g              RSB1/YOR049c                Sphingolipid transporter; involved in fatty acid transport                                                    2.1631

The *Candida glabrata erg1* mutant CgTn201S vs. the parental wild-type Cg1660.

###### 

Functional enrichment with associated genes identified by using Cytoscape and GO database.

  Enriched process              Associated gene                                             P-value
  ----------------------------- ----------------------------------------------------------- -----------------
  Sterol biosynthetic process   *CYB5, ERG2, ERG3, ERG5, ERG6, ERG7, ERG10, ERG11, ERG29*   \<0.0005
  Lipid localization            *AUS1, DAN1, RSB1*                                          0.0005 to 0.005

GO, Gene Ontology.

###### 

Inhibitory effect of azoles in *Candida glabrata* wild-type, *erg1* mutant, and *erg1/aus1∆* double mutant on MIN agar medium with sterol supplement under hypoxic condition.

                     E-test on MIN agar medium                     
  ------------------ --------------------------- ---- ---- ------- -------
  Cg1660             −                           −    −    \>256   4.0
  Cg1660             \+                          −    −    \>256   4.0
  Cg1660             \+                          \+   −    \>256   12
  Cg1660             \+                          −    \+   \>256   12
  CgTn201S           −                           −    −    0.50    0.064
  CgTn201S           \+                          −    −    0.50    0.064
  CgTn201S           \+                          \+   −    \>256   \>32
  CgTn201S           \+                          −    \+   \>256   \>32
  CgTn201Su/Cgaus1   −                           −    −    0.50    0.064
  CgTn201Su/Cgaus1   \+                          −    −    0.50    0.064
  CgTn201Su/Cgaus1   \+                          \+   −    0.50    0.064
  CgTn201Su/Cgaus1   \+                          −    \+   0.50    0.064

Under hypoxic conditions (1% O~2~). Cg1660, *C. glabrata* wild-type; CgTn201S, *C. glabrata erg1* mutant; CgTn201S/Cgaus1, *C. glabrata erg1/aus1Δ* double mutant; EtOH, ethanol; MIC, minimum inhibitory concentration.

###### 

Inhibitory effect of azoles in *Candida glabrata* wild-type, *erg1* mutant, and *erg1/aus1∆* double mutant on YEPG agar medium with sterol supplement under hypoxic condition.

                     E-test on YEPG agar medium                     
  ------------------ ---------------------------- ---- ---- ------- -------
  Cg1660             −                            −    −    \>256   1.0
  Cg1660             \+                           −    −    \>256   1.0
  Cg1660             \+                           \+   −    \>256   1.0
  Cg1660             \+                           −    \+   \>256   6.0
  CgTn201S           −                            −    −    1.0     0.064
  CgTn201S           \+                           −    −    1.0     0.064
  CgTn201S           \+                           \+   −    \>256   \>32
  CgTn201S           \+                           −    \+   \>256   \>32
  CgTn201Su/Cgaus1   −                            −    −    1.0     0.064
  CgTn201Su/Cgaus1   \+                           −    −    1.0     0.064
  CgTn201Su/Cgaus1   \+                           \+   −    1.0     0.064
  CgTn201Su/Cgaus1   \+                           −    \+   1.0     0.064

Under hypoxic conditions (1% O~2~). Cg1660, *C. glabrata* wild-type; CgTn201S, *C. glabrata erg1* mutant; CgTn201S/Cgaus1, *C. glabrata erg1/aus1Δ* double mutant; EtOH, ethanol; MIC, minimum inhibitory concentration.
